NASDAQ
13.02.26 | 21:59
10,635 US-Dollar
-2,07 % -0,225
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.02. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.01. | Fulcrum Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.01. | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 21.12.25 | Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study | 3 | Insider Monkey | ||
| FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data | 1 | Investing.com | ||
| 10.12.25 | Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants | 4 | Seeking Alpha | ||
| 10.12.25 | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 08.12.25 | Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock | 1 | Seeking Alpha | ||
| 08.12.25 | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 08.12.25 | Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results | 2 | Benzinga.com | ||
| 08.12.25 | Stifel raises Fulcrum Therapeutics stock price target to $25 on strong ASH data | 1 | Investing.com | ||
| 08.12.25 | Goldman Sachs reiterates rating on Fulcrum Therapeutics stock after positive trial data | 3 | Investing.com | ||
| 08.12.25 | Goldman Sachs bekräftigt Rating für Fulcrum Therapeutics nach positiven Studiendaten | 2 | Investing.com Deutsch | ||
| 08.12.25 | BofA Securities raises Fulcrum Therapeutics stock price target on SCD drug data | 3 | Investing.com | ||
| 08.12.25 | Fulcrum Therapeutics stock price target raised to $25 from $18 at H.C. Wainwright | 2 | Investing.com | ||
| 08.12.25 | Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results | 4 | Seeking Alpha | ||
| 08.12.25 | Fulcrum Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Leerink Partners raises Fulcrum Therapeutics stock price target on strong sickle cell data | 5 | Investing.com | ||
| 08.12.25 | Fulcrum Therapeutics stock price target raised to $10 from $7 at RBC Capital | 1 | Investing.com | ||
| 06.12.25 | Fulcrum Therapeutics: Starke Studiendaten für Sichelzell-Medikament Pociredir | 4 | Investing.com Deutsch |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,280 | +1,00 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| MODERNA | 35,655 | +0,28 % | BioNTech-Konkurrent Moderna: Rückschlag - Aktie rauscht erneut nach unten | Wie jüngst bekannt wurde, weigert sich die US-Arzneimittelbehörde FDA, den Zulassungsantrag für den experimentellen Grippeimpfstoff mRNA-1010 überhaupt zu prüfen. Die Aktie von Moderna geriet am Dienstag... ► Artikel lesen | |
| VALNEVA | 4,200 | -2,64 % | Valneva Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom | Lyon (France), February 13, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's... ► Artikel lesen | |
| AMGEN | 310,90 | -0,02 % | Dividendenbekanntmachungen (13.02.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,78 USD 0,6571 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0505 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| NOVAVAX | 7,330 | +0,10 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| STRYKER | 307,50 | -0,26 % | Stryker Launches T2 Alpha Humerus Nailing System for Fracture Care | ||
| BIOGEN | 166,55 | +1,99 % | Biogen Inc.: Biogen Announces Board Chair Transition | Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new ChairCAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB)... ► Artikel lesen | |
| ILLUMINA | 97,90 | -0,51 % | Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips | ||
| CRISPR THERAPEUTICS | 44,200 | -1,34 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 675,60 | -0,12 % | Regeneron Pharmaceuticals, Inc.: Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy | 36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,330 | +0,92 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,320 | -0,55 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity... ► Artikel lesen | |
| EDITAS MEDICINE | 1,478 | -0,57 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,410 | +2,50 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien |
FULCRUM THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,07 % bei einem Aktienkurs von 10,635 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FULCRUM THERAPEUTICS INC finden Sie auf Wallstreet Online.